期刊文献+

比格犬与人体胃肠道的生理学差异及其对口服缓控释制剂体内评价的影响 被引量:6

下载PDF
导出
摘要 禁食状态下,比格犬胃排空时间与胃液pH值和人体类似。进食后,比格犬和人体胃排空时间均显著延长,且对前者的影响更大。进食后,由于食物的缓冲作用,人体胃液pH值升高,其后由于胃酸的分泌重新下降。比格犬在进食后胃液pH值能维持在相对稳定的状态。人体与比格犬的小肠转运时间均不受进食状态和剂型的影响,溶液剂、颗粒剂和片剂具有类似的小肠转运时间。人体的小肠转运时间约为3-5h,比格犬的小肠转运时间约为2-3h。对于仅在小肠吸收的药物的缓控释制剂,比格犬生物利用度试验可能导致对其人体内实际吸收量的低估,造成不必要的处方优化。比格犬与人体小肠液pH值接近,均约为6.2-7.5。比格犬胃肠道的搅拌强度和对制剂的破坏力强于人体,导致缓控释制剂释放和吸收速度加快。
作者 付静静
出处 《科技信息》 2010年第32期I0196-I0196,共1页 Science & Technology Information
  • 相关文献

参考文献15

  • 1Willmann,S.,Thelen,K.,Becker,C.,Dressrnan,J.B.,Lippert,J.,2010.Mechanism-based prediction of particle size-dependent dissolution and absorption:Cilostazol pharmacokinetics in dogs.76,83-94.
  • 2Jantratid,E..Maio,V.D.,Ronda,E.,Mattavelli,V.,Vertzoni,M.,Dressman,J.B.,2009.Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form.37,434-441.
  • 3Murata,S.,Ueda,S.,Shimojo,F.,Tokunaga,Y.,Hata,T.,Ohnishi,N.,1998.In vivo performance of time-controlled explosion system (TES)in GI physiology regulated dogs.Int.J.Pharm.161,161-168.
  • 4Davies,N.M.,Anderson,K.E.,1997.Clinical pharmacokinetics of diclofenac.Therapeutic insights and pitfalls.Clin.Phatmacokinet.33,184-213.
  • 5Kabanda,L.,Lefebvre,R.A.,Bree,H.J.V.,Remon,J.P.,1994.In vitro and in vivo evaluation in Dogs and Pigs of a Hydrophilic Matrix Containing Propylthiouracil.Pharm.Res.11,1663-1668.
  • 6Dressman,I.B.,1986.Comparison of Canine and Human Gastrointestinal Physiology.Pharm.Res.3,123-131.
  • 7Katori,N.,Aoyagi,N.,Terao,T.,1995.Estimation of agitation intensity in the GI tract in Humans and dogs based on in vitro/in vivo correlation.Pharm.Res.12,237-243.
  • 8Kamba,M.,Seta,Y.,Kusai,A.,Ikeda,M.,Nishimura,K.,2000.A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal]tract,Int.J.Pharm.208,61-70.
  • 9Brockmeier,D.,Dengler,H.J.,Voegele,D.,1985.In vitro-in vivo correlation of dissolution,a time scaling problem? Transformation of in vitro results to the in vivo situation,using theophylline as a practical example.Eur.J.Pharmacol.28,291-300.
  • 10Dietrich,R.,Brausse,R.,Benedikt,G.,Steinijans,V.W.,1988.Feasibility of in vitro/in vivo correlation in the case of a new sustained-release theophylline pellet formulataon.Arzneim.-Forsch.38,1229-1237.

同被引文献43

引证文献6

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部